Infliximab for ulcerative colitis.
In an interim analysis of a randomized, double-blind trial that was ended early because of slow enrollment and ethical issues, significantly fewer patients (7 of 24) who received an infusion of infliximab had a colectomy within 90 days than did patients who received placebo (14 of 21). Treatment with infliximab was associated with a significant, nearly fivefold higher likelihood of remaining free of colectomy than was placebo. Two additional patients in each group had a colectomy after 6 months of follow-up (Gastroenterology 2005;128:1805-11).
Maintenance treatment with repeated infliximab infusions will probably be needed for patients with ulcerative colitis, just as it has been for patients with Crohn's disease, especially "in patients who escape a colectomy to avoid further hospitalizations and risk of later surgery," Geert D'Haens, M.D., of the Imelda GI Clinical Research Center, Bonheiden, Belgium, said in an editorial (Gastroenterology 2005;128:2161-4). Centocor, the maker of infliximab (Remicade), did not sponsor the trial.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||CLINICAL CAPSULES|
|Publication:||Internal Medicine News|
|Article Type:||Brief article|
|Date:||Jul 15, 2005|
|Previous Article:||Bowel sounds did not flag recovery from abdominal surgery.|
|Next Article:||Mycobacterial cause of Crohn's?|